← Back to guidelines
Allergy & Immunology9 papers

Peripheral T-cell lymphoma (clinical)

Last edited: 4/15/2026

Overview

Peripheral T-cell lymphoma (PTCL) encompasses a heterogeneous group of non-Hodgkin lymphomas originating from mature T or natural killer (NK) cells, often presenting with diverse morphological and immunophenotypic features 1.

Diagnosis

  • Immunophenotyping: Essential for classification; includes evaluation of CD3, CD5, CD7, CD30 expression, and others to distinguish subtypes 1.
  • EBV Testing: Epstein-Barr virus (EBV) EBER1/2 hybridization recommended to assess potential association with certain subtypes 1.
  • Morphological Assessment: Critical for identifying broad spectrum of presentations within PTCL subtypes 1.
  • WHO Classification: Cases reviewed and classified according to the WHO classification system for lymphoid neoplasms 1.
  • Management

  • First-Line Treatment: Chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) are commonly used, though efficacy varies by subtype 1.
  • Subtype-Specific Approaches: Certain subtypes like enteropathy-associated T-cell lymphoma may require tailored treatments beyond standard CHOP 1.
  • Adjunctive Therapies: Rituximab may be considered in specific cases, particularly those with B-cell markers or EBV positivity 1.
  • Clinical Trials: Encouraged for patients with refractory or relapsed disease due to limited evidence for standard treatments 1.
  • Special Populations

  • Elderly Patients: Treatment strategies often adjusted for comorbidities and performance status; less robust evidence exists for specific elderly protocols 1.
  • Comorbidities: Management must consider coexisting conditions, potentially influencing treatment choice and intensity 1.
  • Key Recommendations

  • Utilize comprehensive immunophenotyping and morphological assessment for accurate PTCL classification (Evidence: Moderate 1).
  • Incorporate EBV testing to guide management decisions, especially in subtypes with potential viral associations (Evidence: Moderate 1).
  • Tailor first-line chemotherapy based on PTCL subtype, considering CHOP as a foundational regimen with modifications as needed (Evidence: Expert opinion 1).
  • References

    1 Kluin PM, Feller A, Gaulard P, Jaffe ES, Meijer CJ, Müller-Hermelink HK et al.. Peripheral T/NK-cell lymphoma: a report of the IXth Workshop of the European Association for Haematopathology. Histopathology 2001. link

    Original source

    1. [1]
      Peripheral T/NK-cell lymphoma: a report of the IXth Workshop of the European Association for Haematopathology.Kluin PM, Feller A, Gaulard P, Jaffe ES, Meijer CJ, Müller-Hermelink HK et al. Histopathology (2001)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG